to a greater impact of adverse effects and a lower chance of successful viral clearance compared with treatment at the compensated stage of cirrhosis. 4, 5 New interferon-free therapies with better tolerability, greater safety and simplified monitoring protocols promise improved treatment options for those with severe liver disease. [6] [7] [8] Importantly,
to assess the clinical value of these new therapies, we need to have a thorough understanding of the extent of mortality and morbidity among DC patients.
A national record-linkage study conducted previously in Scotland for the period 1991-2005 reported an average annual increase of 10 .7% in the number of new presentations with HCV-related DC.
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The risk of developing DC in this population was found to be associated with epidemiological characteristics including older age, a history of problem alcohol use and HIV coinfection. Outcomes following DC were not investigated; in the current study, we expand upon this earlier research by setting this rising trend in the annual number of DC cases in context of the disease burden experienced by these patients.
Therefore, the principal purpose of this study was to further our understanding of the natural history of HCV-related DC during the pre-DAA (direct-acting antivirals) era, so that we can assess the impact of highly effective DAA regimens-now being introduced-on the risk of death from liver failure and the development of such complications as hepatocellular carcinoma (HCC). These findings will constitute a historical baseline against which future outcomes can be gauged. In this study, we describe the frequency of liver-related and all-cause mortality and first-time hospital admissions for HCC among Scotland's HCV-infected DC patient population and report the risk of mortality and associated patient factors.
| MATERIALS AND METHODS

| Design
The design was a retrospective cohort study, using record-linkage between national databases to determine the health burden among HCV chronically infected persons who have reached the DC stage of liver disease. 
| Data sources
Health
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The Scottish Hepatitis C Clinical database, also held at Health 
| Record linkage
Linkage of records between the HCV Diagnosis database and the Linkages were approved by the Privacy Advisory Committee, which oversees confidentiality issues involving data held on NHS Scotland patients.
| Data analysis
| Study population
The study population consisted of all HCV chronically infected patients with diagnosed DC (defined as first inpatient/day-case hospital episode with a relevant ICD-9 or ICD-10 code in either the main or five supplementary diagnosis fields of the episode record) in Scotland over the period 1994-2013, thus providing a 20-year study period.
Individuals for whom their first DC hospital admission occurred >1 year before their HCV diagnosis were excluded, to reduce potential bias due to DC resulting from another aetiology. and hepatorenal syndrome (ICD-10 K76.7; ICD-9 572.4). These codes were common among those used in previous DC research 9, 16 and were selected in consultation with clinicians and epidemiologists working in the field of HCV infection.
| Outcome measures and covariates
We report three principal endpoints: liver-related mortality, all-cause mortality and first HCC admission subsequent to first DC admission, 
| Statistical analyses
The average annual percentage change in the number of new DC patients, both overall and stratified by covariate level, was calculated by fitting Poisson regression models to the annual observed numbers over the period 1994-2013. Cumulative incidence plots, per outcome, were produced using a multistate modelling/competing risk approach. 18 Transition probabilities between disease states were estimated using the same multistate model; we report annual values by averaging over the estimated probabilities for each of the first 3 years of follow-up.
| Follow-up time
We used standard person-time methodology. For each endpoint investigated, the follow-up period was defined to begin at the date of the first hospital admission with mention of DC and to end at the earliest of the date the endpoint occurred or the right-censoring date (31 May 2014). Follow-up was also censored at date of death from a nonliver-related cause or from any cause in the analyses of the endpoints liver-related mortality and first HCC admission, respectively.
Cox regression analyses were carried out to estimate the relative risk (as hazard ratios) of all-cause and liver-related mortality associated with the covariates of interest. Violation of the proportional hazards assumption was graphically assessed and additionally tested using Schoenfeld residuals.
Finally, we assessed the presence and impact of potential referral bias that can be present when analysing a prevalent cohort (ie, the chance of inclusion in the study population may be associated with the outcome(s) of interest; this may be the case for patients who died of DC that had been first diagnosed only at a very advanced stage).
Therefore, as a sensitivity analysis, the Cox regression analyses were repeated, but with the follow-up period redefined to exclude the first 14 days after first DC admission. All statistical analyses were conducted using R software for statistical computing. 
| RESULTS
| First-time hospitalization for DC
During the period 1994-2013, a total of 1169 HCV chronically infected persons were hospitalized with first-time mention of DC ( Table 1 ). The majority were males (74%), and the most frequent age-group was 40-49 years (39%). More than half (56%) had an alcohol-related admission prior to their first DC admission, and injecting drug use was indicated as the risk activity for acquiring HCV infection for 46% of the study population (85% of those with known risk). 
| Annual change in the number of first-time admissions for DC
The annual numbers of new DC patients, both overall and stratified by DC code category, are shown in Figure 1A . The average annual percentage change in the numbers of DC patients by stratum of covariate is presented in The rates of liver-related and nonliver-related mortality dropped rapidly over the initial 6 months following first DC admission (very high in the first 2-week period) and then decreased more gradually with time since DC (Table S1 ). Mortality rates for both endpoints were relatively stable over the four quinquennia of the study period (data not shown).
The annual transition probabilities between various disease states are shown in Figure 2 . The probability of a liver-related death following first DC admission was 20.9%, higher than the probability of either nonliver-related death or first subsequent HCC admission (3.0% and 1.5% per year, respectively). Following the first subsequent HCC admission, the annual transition probabilities for liver-related and nonliver-related mortality were 52.4% and 0%, respectively. Figure 3 shows the proportion of the DC cohort in each disease state (the state occupation probabilities) over the first 9 years of follow-up. Figure 4 shows the cumulative risks of each of the four outcomes; the cumulative risks for the same four endpoints but stratified according PWID, people who inject drugs; HCC, hepatocellular carcinoma. Study population is defined as first hospital admission with mention of DC occurring within the period 1994-2013 (n=1169). The average annual per cent change over the study period in the number of DC patients is also shown (12.6% overall). *P-values for annual percentage change are all <.01, except for ′HIV code in any admission=yes′ (P=.0169). a Because more than one code category can appear in the hospital episode record of an individual patient, a hierarchical definition was used; for example if a hepatic failure code occurs in one of six possible diagnosis fields, DIAG1 (primary diagnosis) through DIAG6 (supplementary diagnoses), the patient will be counted as such, even if one or more of the other code categories also occurred in the hospital record. If no hepatic failure code but an ascites code occurs in any of the diagnosis fields, then category "ascites" is assigned, and so forth.
| Survival analysis of time to outcome
to DC code category and according to the occurrence of at least one alcohol-related admission prior to first DC admission are provided in
Figures S1 and S2. The 5-year cumulative risks of liver-related mortality, all-cause mortality, nonliver-related mortality and first subsequent HCC admission were 61.3%, 69.5%, 8.2% and 8.8%, respectively. If patients with an HCC admission prior to study entry are excluded, the 5-year cumulative risk of a first HCC admission decreases to 6.4%.
The results of the multifactorial Cox proportional hazards regression analyses of liver-related and all-cause mortality are presented in Table 2 , with univariate Cox regression results in Table S2 . The relative risk of liver-related death among DC patients was significantly increased for males (HR=1.3, 95% CI: 1.1-1.6), current age 60+ years Table 2) . (Table S3 ).
For liver-related deaths only, the five most frequently occurring ICD codes in the underlying cause of death field were K70.9, B182, C220, K703 and K704 (alcoholic liver disease, unspecified, chronic hepatitis C, liver cancer, cirrhosis and alcoholic hepatic failure, respectively), which together accounted for 62% (445/722) of all liver-related deaths. For nonliver-related deaths only, the five most frequently occurring underlying cause of death ICD codes were R99, F112, F192, X42 and I189 (other ill-defined and unspecified causes of mortality, mental/behavioural disorders due to use of opioids, mental/ behavioural disorders due to multiple drug use, accidental poisoning by and exposure to narcotics and psychodysleptics, other noninfective disorders of lymphatic vessels and lymph nodes, respectively), which together accounted for 41% (39/95) of the total.
| DISCUSSION
Scotland has been experiencing an epidemic of HCV-related decom- Over the 20-year study period, we found no evidence for improvement in the relative risks of liver-related or all-cause mortality associated with quinquennium of first DC hospitalization. Despite remarkable increases in rates of referral to tertiary care (ie, specialist liver clinics) and of initiation on antiviral treatment among HCV-infected patients in recent years in Scotland, 13 mortality outcomes failed to show parallel improvements once the DC stage of liver disease had been reached.
Moreover, the 5-year cumulative incidence of all-cause mortality was notably high-at 70%-in this DC patient population, even though we lacked accurate data on liver transplantation. In a comparable period (1996-2014, mostly overlapping our study period), there were 176 first liver transplants in HCV-infected persons in Scotland
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; a proportion of the observed extended survival in DC patients with liver failure (see Figure 3 ) may be due to successful transplantation (we estimate 50% as an upper bound; 176 represents 50% of our cohort′s 5-year survivors). However, in multifactorial analyses, we did adjust for an 17% developed HCC and all-cause mortality was 43%. 21, 22 In a larger clinical cohort study involving 1037 HCV-infected/HIV-uninfected persons from eight Spanish hospitals followed up for a median 13 months, 37% of patients died, of which 86% was due to a liverrelated cause. 23 There is uncertainty, however, in generalizing findings based on primarily academic research centre clinical populations, which may be subject to selection bias, to the wider DC patient population. For instance, 5-year survival in DC patients reported for an HCV patient cohort 21 was notably better: 51% compared with 30% for our cohort; for comparison, the 5-year cumulative mortality incidence from a systematic review of disease progression in cirrhotic patients (not only due to HCV infection) is roughly 75%. 24 Our estimate of the annual transition probability of death following DC (24%; summing liver-related and nonliver-related causes) is also much higher than the pooled estimate of 14.5% arrived at via meta-analysis of three clinical cohorts.
1-3,25
Development of HCC or death following DC may be influenced by underlying comorbidities. 26 For instance, our study population had a high baseline rate (56%) of prior hospitalization for an alcohol-related cause, which we included as an (imperfect) proxy for problem alcohol use. However, we found no evidence for an effect of alcohol-related hospitalization (proxy for problem alcohol use) on the relative risk of death, after adjusting for other covariates. Although Scotland's HCVdiagnosed population has a high prevalence of problem alcohol use, alcohol-related liver disease as a comorbid condition is also characteristic of other, mainly substance-abusing, HCV-infected populations. 26, 27 We emphasize the importance of quantifying the benefit of treatment with the new DAAs among all DC patients-including those with extensive comorbidities-in terms of survival, and not just a sustained virological response. 28 Record-linkage methods similar to those described here may prove useful for establishing the prognosis of patients treated with DAAs and attaining SVR post-DC diagnosis.
Despite the power and large sample size afforded by our record- ]. This suggests a reason for the observed lack of association of this covariate with mortality in multifactorial analysis.
Our study inclusion criteria required a first hospital admission for DC. Record linkage to hospital inpatient data should have high sensitivity as almost all DC patients will be admitted to hospital. However, an unknown number of persons developing DC and who were not admitted to hospital will have been excluded. This number is likely to be very small given that in the previous Scottish record-linkage analysis of HCV-diagnosed patients developing DC in the period 1996-2006, 9 only 6% (63/1058) of those patients who had died with mention of DC in their death record had not been previously admitted to hospital. Finally, we have not been able to follow-up those DC patients who were hospitalized or who had died outwith Scotland, although these numbers are anticipated to be small.
| CONCLUSIONS
Over the last 20 years, there has been no observable improvement in severe outcomes among HCV chronically infected patients in Scotland who have developed decompensated cirrhosis. The annual numbers of incident and prevalent DC cases showed a rising trend, and the relative risks of all-cause and liver-related death did not vary over the study period. The present results are important for establishing the expected risks of severe disease outcomes among DC patients in the interferon-based treatment era and will be useful for calibrating and/or validating HCV disease projection and health economic models. [30] [31] [32] Further monitoring of the numbers of incident and prevalent DC cases, and the risks of death and complications among persons with DC, is of utmost importance in the era of new DAA treatments.
